Individualized anemia management reduces hemoglobin variability in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 25, Issue 1, 2014, Pages 159-166

  Gaweda, Adam E ^a   Aronoff, George R ^a   Jacobs, Alfred A ^a   Rai, Shesh N ^b   Brier, Michael E ^a,c  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; IRON;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

EID: 84891771913     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013010089     Document Type: Article

References (16)

1. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S,Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
2. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
3. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB,McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
4. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de ZeeuwD, Ivanovich P, LeveyAS, Parfrey P, RemuzziG, SinghAK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363: 1146-1155, 2010
5. Collins AJ: ESRD Payment Policy Changes: The New "Bundled" Dialysis Prospective Payment System (PPS) in the United States. Presented at the 2012 National Kidney Foundation Spring Clinical Meeting, Washington, DC, May 9-13, 2012
6. Unger EF, ThompsonAM, BlankMJ, Temple R: Erythropoiesis-stimulating agents-time for a reevaluation. N Engl J Med 362: 189-192, 2010
7. Kliger AS, Fishbane S, Finkelstein FO: Erythropoietic stimulating agents and quality of a patient's life: Individualizing anemia treatment. Clin J Am Soc Nephrol 7: 354-357, 2012
8. Brier ME, Gaweda AE, Dailey A, Aronoff GR, Jacobs AA: Randomized trial of model predictive control for improved anemia management. Clin J Am Soc Nephrol 5: 814-820, 2010
9. Gaweda AE, Jacobs AA, AronoffGR, BrierME:Model predictive control of erythropoietin administration in the anemia of ESRD. Am J Kidney Dis 51: 71-79, 2008
10. Lines SW, Lindley EJ, Tattersall JE, Wright MJ: A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: Better results for less work. Nephrol Dial Transplant 2012;27: 2425-2429
11. Pisoni RL, Fuller DS, Bieber BA, Gillespie BW, Robinson BM: The DOPPS Practice Monitor for US dialysis care: Trends through August 2011. Am J Kidney Dis 60: 160-165, 2012
12. Gaweda AE, Jacobs AA, Brier ME: Application of fuzzy logic to predicting erythropoietic response in hemodialysis patients. Int J Artif Organs 31: 1035-1042, 2008
13. Gaweda AE, Malof JM, AronoffGR, Jacobs AA, BrierME: computer-aided personalized anemia management. J Am Soc Nephrol 21: 107A, 2010
14. Gaweda AE, Brier ME, Aronoff GR: Validation of an intelligent decision support tool for anemia management. J AmSoc Nephrol 22: 480A, 2011
15. Faul F, Erdfelder E, Lang A-G, Buchner A: G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Res Methods 39, 175-191, 2007
16. Taves DR: Minimization: A new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 15: 443-453, 1974